Type 1 diabetes
Also known as: insulin-dependent diabetes · T1D · T1DM
Free to read — no account needed. Sign in only to bookmark this disease and track your study progress.
Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026 (Section 9)
American Diabetes Association (ADA) · 2026
The ADA's annually revised Standards of Care set out its current recommendations for glucose-lowering therapy; the pharmacologic section covers insulin regimens for type 1 diabetes, including basal-bolus and pump-based approaches.
The Management of Type 1 Diabetes in Adults: A Consensus Report by the ADA and EASD
EASD (joint consensus with ADA) · 2021
This joint ADA/EASD consensus report describes an overall approach to caring for adults with type 1 diabetes, spanning diagnosis, education and support, monitoring, insulin delivery and acute complications.
- The report covers diagnosis, self-management education, glucose monitoring, insulin therapy, hypoglycaemia, psychosocial care, ketoacidosis, transplantation and adjunctive therapies. source
- It deliberately excludes detailed treatment of long-term complications, which are addressed in other documents. source
US vs EU key differences
- Technology stance differs by generation: the 2026 ADA Standards make automated insulin delivery the preferred insulin-delivery method for people with type 1 diabetes, whereas the 2021 ADA/EASD consensus still framed fully closed-loop systems as an emerging technology. source
- The 2026 US standards explicitly remove prerequisites for starting pump or automated insulin delivery therapy — no required C-peptide level, islet autoantibody result, or minimum duration of insulin treatment. source
- Document type differs: the EU/global item is a one-off joint ADA–EASD consensus report that deliberately excludes chronic complications and does not attempt to replicate existing guidance, while the US item is a section of an annually revised standards-of-care document. source
- Version currency differs sharply: the joint ADA/EASD type 1 consensus dates to 2021 and has not been reissued, against a US standard refreshed for 2026. source
What changed recently
- US2025 → 20262026-01-01
For insulin-treated diabetes the 2026 edition broadened continuous glucose monitoring to be offered at diagnosis and at any later point (Rec 9.25), and strengthened the recommendation that automated insulin delivery systems be offered to eligible adults. A new recommendation also addresses screening for insulin need and ketoacidosis risk in immune checkpoint inhibitor-associated diabetes.
See the full update feed for changes across every system.